Advanced search×

Estrogen, hormonal replacement therapy and cardiovascular disease.

Xiao-Ping Yang and Jane F Reckelhoff

Curr Opin Nephrol Hypertens 20(2):133-8 (2011) PMID 21178615

Premenopausal women have a lower risk and incidence of hypertension and cardiovascular disease (CVD) compared to age-matched men and this sex advantage for women gradually disappears after menopause, suggesting that sexual hormones play a cardioprotective role in women. However, randomized prospective primary or secondary prevention trials failed to confirm that hormone replacement therapy (HRT) affords cardioprotection. This review highlights the factors that may contribute to this divergent outcome and could reveal why young or premenopausal women are protected from CVD and yet postmenopausal women do not benefit from HRT.

DOI: 10.1097/MNH.0b013e3283431921
Version: za2963e q8za3 q8zb1 q8zcc q8zd7 q8ze9 q8zf5 q8zgf
View PDF

Similar articles you may find interesting…

  1. Recombinant hormones in osteoporosis.
    Lars Rejnmark

    Expert Opin Biol Ther (2013) PMID 23646915

    For the last 10 years, bone anabolic therapy with the recombinant human parathyroid hormone (rhPTH) analogue, teriparatide (rhPTH[1-34]), or full-length rhPTH(1-84) has been an option in the treatment of osteoporosis. Both drugs are given as a daily subcutaneous injection. In the USA, only teriparat...
    Buy PDF
  2. Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.
    Mario Acunzo, Giulia Romano, and Carlo M Croce

    Proc Natl Acad Sci U S A (2013) PMID 23650389

    We have observed exciting advances in lung cancer therapy, including the development of targeted therapies. However, additional strategies for early detection and tumor-based therapy are still essential in improving patient outcomes. EGF receptor (EGFR) and MET (the receptor tyrosine kinase for hepa...
    Buy PDF
  3. Predictors of Mortality and Outcomes of Therapy in Low Flow Severe Aortic Stenosis: A PARTNER Trial Analysis.
    Howard C Herrmann, Philippe Pibarot, and Martin B Leon

    Circulation (2013) PMID 23661722

    Low flow is common in severe AS and independently predicts mortality. Survival is improved with TAVR as compared to MM and similar with TAVR and SAVR. A measure of flow (SVI) should be included in the evaluation and therapeutic decision making of patients with severe AS. CLINICAL TRIAL REGISTRATION...
    Buy PDF